中国神经再生研究(英文版) ›› 2017, Vol. 12 ›› Issue (9): 1422-1425.doi: 10.4103/1673-5374.215245

• 综述:退行性病与再生 • 上一篇    下一篇

免疫方法治疗亨廷顿病的承诺和陷阱

  

  • 收稿日期:2017-08-22 出版日期:2017-09-15 发布日期:2017-09-15

Promises and pitfalls of immune-based strategies for Huntington’s disease

Gabriela Delevati Colpo1, Erin Furr Stimming2, Natalia Pessoa Rocha1, Antonio Lucio Teixeira1   

  1. 1 Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
    2 Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
  • Received:2017-08-22 Online:2017-09-15 Published:2017-09-15
  • Contact: Antonio Lucio Teixeira,Antonio.L.Teixeira@uth.tmc.edu

摘要:

 

 

orcid:0000-0002-9621-5422(Antonio Lucio Teixeira)

Abstract:

Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disease characterized by the selec­tive loss of neurons in the striatum and cortex, leading to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide (CAG) repeat expansion in the gene encoding for huntingtin. Several studies have suggested that inflammation is an important feature of HD and it is already observed in the early stages of the disease. Recently, new molecules presenting anti-inflammatory and/or immunomodulatory have been investigated for HD. The objective of this review is to discuss the data obtained so far on the immune-based therapeutic strategies for HD.

Key words: Huntington’s disease, treatment, disease modifying therapy, inflammation